Alpha Tau Medical (DRTS) Competitors

$9.64 -0.24 (-2.43%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$9.54 -0.10 (-1.03%)

As of 04:24 AM Eastern

DRTS vs. LMAT, WRBY, AXGN, ESTA, and NVCR

Should you buy Alpha Tau Medical stock or one of its competitors? MarketBeat compares Alpha Tau Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alpha Tau Medical include LeMaitre Vascular (LMAT), Warby Parker (WRBY), AxoGen (AXGN), Establishment Labs (ESTA), and NovoCure (NVCR). These companies are all part of the "medical equipment" industry.

How does Alpha Tau Medical compare to LeMaitre Vascular?

LeMaitre Vascular (NASDAQ:LMAT) and Alpha Tau Medical (NASDAQ:DRTS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

In the previous week, LeMaitre Vascular had 1 more articles in the media than Alpha Tau Medical. MarketBeat recorded 18 mentions for LeMaitre Vascular and 17 mentions for Alpha Tau Medical. LeMaitre Vascular's average media sentiment score of 0.52 beat Alpha Tau Medical's score of 0.22 indicating that LeMaitre Vascular is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	7 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alpha Tau Medical	1 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 2.7% of Alpha Tau Medical shares are held by institutional investors. 7.4% of LeMaitre Vascular shares are held by insiders. Comparatively, 39.5% of Alpha Tau Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

LeMaitre Vascular has a net margin of 24.35% compared to Alpha Tau Medical's net margin of 0.00%. LeMaitre Vascular's return on equity of 15.36% beat Alpha Tau Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
Alpha Tau Medical	N/A	-57.29%	-42.39%

LeMaitre Vascular has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	8.99	$57.73M	$2.71	36.23
Alpha Tau Medical	N/A	N/A	-$42.63M	-$0.53	N/A

LeMaitre Vascular presently has a consensus price target of $112.60, suggesting a potential upside of 14.70%. Alpha Tau Medical has a consensus price target of $10.75, suggesting a potential upside of 11.51%. Given LeMaitre Vascular's stronger consensus rating and higher possible upside, research analysts clearly believe LeMaitre Vascular is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Alpha Tau Medical	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

LeMaitre Vascular has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Alpha Tau Medical has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

Summary

LeMaitre Vascular beats Alpha Tau Medical on 14 of the 16 factors compared between the two stocks.

How does Alpha Tau Medical compare to Warby Parker?

Warby Parker (NYSE:WRBY) and Alpha Tau Medical (NASDAQ:DRTS) are both medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Warby Parker has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Warby Parker	$871.91M	3.50	$1.64M	$0.02	1,423.85
Alpha Tau Medical	N/A	N/A	-$42.63M	-$0.53	N/A

Warby Parker presently has a consensus price target of $29.00, suggesting a potential upside of 1.84%. Alpha Tau Medical has a consensus price target of $10.75, suggesting a potential upside of 11.51%. Given Alpha Tau Medical's higher possible upside, analysts clearly believe Alpha Tau Medical is more favorable than Warby Parker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Warby Parker	0 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.63
Alpha Tau Medical	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Warby Parker had 6 more articles in the media than Alpha Tau Medical. MarketBeat recorded 23 mentions for Warby Parker and 17 mentions for Alpha Tau Medical. Warby Parker's average media sentiment score of 0.51 beat Alpha Tau Medical's score of 0.22 indicating that Warby Parker is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Warby Parker	9 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alpha Tau Medical	1 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

93.2% of Warby Parker shares are held by institutional investors. Comparatively, 2.7% of Alpha Tau Medical shares are held by institutional investors. 16.8% of Warby Parker shares are held by insiders. Comparatively, 39.5% of Alpha Tau Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Warby Parker has a net margin of 0.15% compared to Alpha Tau Medical's net margin of 0.00%. Warby Parker's return on equity of 2.30% beat Alpha Tau Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Warby Parker	0.15%	2.30%	1.18%
Alpha Tau Medical	N/A	-57.29%	-42.39%

Warby Parker has a beta of 1.95, meaning that its stock price is 95% more volatile than the broader market. Comparatively, Alpha Tau Medical has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

Summary

Warby Parker beats Alpha Tau Medical on 13 of the 15 factors compared between the two stocks.

How does Alpha Tau Medical compare to AxoGen?

Alpha Tau Medical (NASDAQ:DRTS) and AxoGen (NASDAQ:AXGN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

AxoGen has higher revenue and earnings than Alpha Tau Medical. AxoGen is trading at a lower price-to-earnings ratio than Alpha Tau Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Tau Medical	N/A	N/A	-$42.63M	-$0.53	N/A
AxoGen	$225.21M	9.51	-$15.70M	-$0.64	N/A

Alpha Tau Medical currently has a consensus price target of $10.75, suggesting a potential upside of 11.51%. AxoGen has a consensus price target of $46.50, suggesting a potential upside of 15.41%. Given AxoGen's stronger consensus rating and higher probable upside, analysts clearly believe AxoGen is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Tau Medical	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
AxoGen	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Alpha Tau Medical had 5 more articles in the media than AxoGen. MarketBeat recorded 17 mentions for Alpha Tau Medical and 12 mentions for AxoGen. AxoGen's average media sentiment score of 0.24 beat Alpha Tau Medical's score of 0.22 indicating that AxoGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Tau Medical	1 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
AxoGen	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

2.7% of Alpha Tau Medical shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 39.5% of Alpha Tau Medical shares are held by company insiders. Comparatively, 2.4% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Alpha Tau Medical has a net margin of 0.00% compared to AxoGen's net margin of -13.21%. AxoGen's return on equity of -9.63% beat Alpha Tau Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Tau Medical	N/A	-57.29%	-42.39%
AxoGen	-13.21%	-9.63%	-6.26%

Alpha Tau Medical has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, AxoGen has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market.

Summary

AxoGen beats Alpha Tau Medical on 10 of the 15 factors compared between the two stocks.

How does Alpha Tau Medical compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and Alpha Tau Medical (NASDAQ:DRTS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Establishment Labs has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Alpha Tau Medical has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

In the previous week, Alpha Tau Medical had 7 more articles in the media than Establishment Labs. MarketBeat recorded 17 mentions for Alpha Tau Medical and 10 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 0.34 beat Alpha Tau Medical's score of 0.22 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alpha Tau Medical	1 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

Establishment Labs currently has a consensus price target of $87.14, suggesting a potential upside of 26.15%. Alpha Tau Medical has a consensus price target of $10.75, suggesting a potential upside of 11.51%. Given Establishment Labs' stronger consensus rating and higher probable upside, research analysts clearly believe Establishment Labs is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Alpha Tau Medical	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Alpha Tau Medical has lower revenue, but higher earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Alpha Tau Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	9.63	-$51.06M	-$1.49	N/A
Alpha Tau Medical	N/A	N/A	-$42.63M	-$0.53	N/A

Alpha Tau Medical has a net margin of 0.00% compared to Establishment Labs' net margin of -19.05%. Alpha Tau Medical's return on equity of -57.29% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
Alpha Tau Medical	N/A	-57.29%	-42.39%

72.9% of Establishment Labs shares are owned by institutional investors. Comparatively, 2.7% of Alpha Tau Medical shares are owned by institutional investors. 10.0% of Establishment Labs shares are owned by insiders. Comparatively, 39.5% of Alpha Tau Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Establishment Labs beats Alpha Tau Medical on 8 of the 15 factors compared between the two stocks.

How does Alpha Tau Medical compare to NovoCure?

NovoCure (NASDAQ:NVCR) and Alpha Tau Medical (NASDAQ:DRTS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

NovoCure has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Alpha Tau Medical has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

In the previous week, Alpha Tau Medical had 15 more articles in the media than NovoCure. MarketBeat recorded 17 mentions for Alpha Tau Medical and 2 mentions for NovoCure. NovoCure's average media sentiment score of 1.67 beat Alpha Tau Medical's score of 0.22 indicating that NovoCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Alpha Tau Medical	1 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

NovoCure currently has a consensus price target of $27.29, suggesting a potential upside of 50.75%. Alpha Tau Medical has a consensus price target of $10.75, suggesting a potential upside of 11.51%. Given NovoCure's stronger consensus rating and higher probable upside, research analysts clearly believe NovoCure is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Alpha Tau Medical	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Alpha Tau Medical has lower revenue, but higher earnings than NovoCure. Alpha Tau Medical is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	3.20	-$136.23M	-$1.53	N/A
Alpha Tau Medical	N/A	N/A	-$42.63M	-$0.53	N/A

Alpha Tau Medical has a net margin of 0.00% compared to NovoCure's net margin of -25.66%. NovoCure's return on equity of -50.82% beat Alpha Tau Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.82%	-16.48%
Alpha Tau Medical	N/A	-57.29%	-42.39%

84.6% of NovoCure shares are owned by institutional investors. Comparatively, 2.7% of Alpha Tau Medical shares are owned by institutional investors. 5.5% of NovoCure shares are owned by insiders. Comparatively, 39.5% of Alpha Tau Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

NovoCure beats Alpha Tau Medical on 9 of the 15 factors compared between the two stocks.

Get Alpha Tau Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DRTS vs. The Competition

Export

Metric	Alpha Tau Medical	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$869.54M	$6.90B	$6.30B	$12.20B
Dividend Yield	N/A	1.72%	2.79%	5.30%
P/E Ratio	-18.19	49.93	21.00	25.58
Price / Sales	N/A	39.66	554.55	78.84
Price / Cash	N/A	24.21	42.94	55.34
Price / Book	10.95	6.49	9.75	6.66
Net Income	-$42.63M	$158.34M	$3.55B	$333.63M
7 Day Performance	22.80%	-1.83%	-0.53%	-0.11%
1 Month Performance	23.12%	-1.10%	1.20%	3.94%
1 Year Performance	240.64%	-2.35%	41.22%	36.07%

Alpha Tau Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DRTS Alpha Tau Medical	2.233 of 5 stars	$9.64 -2.4%	$10.75 +11.5%	+249.3%	$869.54M	N/A	N/A	80	Upcoming Earnings Analyst Forecast Gap Up
LMAT LeMaitre Vascular	4.6415 of 5 stars	$112.00 +0.4%	$105.80 -5.5%	+17.9%	$2.55B	$249.60M	44.62	490	Insider Trade
WRBY Warby Parker	2.7131 of 5 stars	$21.64 -1.6%	$28.09 +29.8%	+54.0%	$2.35B	$871.91M	1,082.59	4,036	Earnings Report Analyst Upgrade
AXGN AxoGen	3.3604 of 5 stars	$43.74 +2.6%	$46.50 +6.3%	+270.3%	$2.27B	$225.21M	N/A	450
ESTA Establishment Labs	3.4806 of 5 stars	$70.99 +1.1%	$86.86 +22.4%	+97.6%	$2.06B	$211.08M	N/A	1,004	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DRTS) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alpha Tau Medical (DRTS) Competitors

DRTS vs. LMAT, WRBY, AXGN, ESTA, and NVCR

How does Alpha Tau Medical compare to LeMaitre Vascular?

Summary

How does Alpha Tau Medical compare to Warby Parker?

Summary

How does Alpha Tau Medical compare to AxoGen?

Summary

How does Alpha Tau Medical compare to Establishment Labs?

Summary

How does Alpha Tau Medical compare to NovoCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRTS vs. The Competition

Alpha Tau Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alpha Tau Medical (DRTS) Competitors

DRTS vs. LMAT, WRBY, AXGN, ESTA, and NVCR

How does Alpha Tau Medical compare to LeMaitre Vascular?

Does the media favor LMAT or DRTS?

Do insiders and institutionals have more ownership in LMAT or DRTS?

Is LMAT or DRTS more profitable?

Which has better valuation & earnings, LMAT or DRTS?

Do analysts rate LMAT or DRTS?

Which has more volatility & risk, LMAT or DRTS?

Summary

How does Alpha Tau Medical compare to Warby Parker?

Which has better valuation & earnings, WRBY or DRTS?

Do analysts rate WRBY or DRTS?

Does the media favor WRBY or DRTS?

Do insiders and institutionals have more ownership in WRBY or DRTS?

Is WRBY or DRTS more profitable?

Which has more volatility & risk, WRBY or DRTS?

Summary

How does Alpha Tau Medical compare to AxoGen?

Which has preferable valuation and earnings, DRTS or AXGN?

Do analysts recommend DRTS or AXGN?

Does the media favor DRTS or AXGN?

Do institutionals and insiders hold more shares of DRTS or AXGN?

Is DRTS or AXGN more profitable?

Which has more risk & volatility, DRTS or AXGN?

Summary

How does Alpha Tau Medical compare to Establishment Labs?

Which has more risk & volatility, ESTA or DRTS?

Does the media refer more to ESTA or DRTS?

Do analysts rate ESTA or DRTS?

Which has higher earnings & valuation, ESTA or DRTS?

Is ESTA or DRTS more profitable?

Do insiders & institutionals hold more shares of ESTA or DRTS?

Summary

How does Alpha Tau Medical compare to NovoCure?

Which has more risk & volatility, NVCR or DRTS?

Does the media refer more to NVCR or DRTS?

Do analysts rate NVCR or DRTS?

Which has higher earnings & valuation, NVCR or DRTS?

Is NVCR or DRTS more profitable?

Do insiders & institutionals hold more shares of NVCR or DRTS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRTS vs. The Competition

Alpha Tau Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools